Alphamab Oncology Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Alphamab Oncology has a total shareholder equity of CN¥1.6B and total debt of CN¥320.0M, which brings its debt-to-equity ratio to 19.6%. Its total assets and total liabilities are CN¥2.1B and CN¥513.3M respectively.

Anahtar bilgiler

19.6%

Borç/özkaynak oranı

CN¥320.00m

Borç

Faiz karşılama oranın/a
NakitCN¥1.46b
EşitlikCN¥1.63b
Toplam yükümlülüklerCN¥513.25m
Toplam varlıklarCN¥2.14b

Son finansal sağlık güncellemeleri

Recent updates

Alphamab Oncology (HKG:9966) Stocks Shoot Up 91% But Its P/S Still Looks Reasonable

Sep 30
Alphamab Oncology (HKG:9966) Stocks Shoot Up 91% But Its P/S Still Looks Reasonable

Some Alphamab Oncology (HKG:9966) Shareholders Look For Exit As Shares Take 48% Pounding

Jun 20
Some Alphamab Oncology (HKG:9966) Shareholders Look For Exit As Shares Take 48% Pounding

Alphamab Oncology's (HKG:9966) Shares Climb 27% But Its Business Is Yet to Catch Up

May 06
Alphamab Oncology's (HKG:9966) Shares Climb 27% But Its Business Is Yet to Catch Up

Optimistic Investors Push Alphamab Oncology (HKG:9966) Shares Up 27% But Growth Is Lacking

Mar 13
Optimistic Investors Push Alphamab Oncology (HKG:9966) Shares Up 27% But Growth Is Lacking

Subdued Growth No Barrier To Alphamab Oncology's (HKG:9966) Price

Jan 17
Subdued Growth No Barrier To Alphamab Oncology's (HKG:9966) Price

Slammed 40% Alphamab Oncology (HKG:9966) Screens Well Here But There Might Be A Catch

May 21
Slammed 40% Alphamab Oncology (HKG:9966) Screens Well Here But There Might Be A Catch

Newsflash: Alphamab Oncology (HKG:9966) Analysts Have Been Trimming Their Revenue Forecasts

Mar 01
Newsflash: Alphamab Oncology (HKG:9966) Analysts Have Been Trimming Their Revenue Forecasts

Is Alphamab Oncology (HKG:9966) Using Debt Sensibly?

Oct 04
Is Alphamab Oncology (HKG:9966) Using Debt Sensibly?

Is Alphamab Oncology (HKG:9966) A Risky Investment?

May 21
Is Alphamab Oncology (HKG:9966) A Risky Investment?

Rock star Growth Puts Alphamab Oncology (HKG:9966) In A Position To Use Debt

Oct 05
Rock star Growth Puts Alphamab Oncology (HKG:9966) In A Position To Use Debt

Is Alphamab Oncology (HKG:9966) Using Too Much Debt?

May 05
Is Alphamab Oncology (HKG:9966) Using Too Much Debt?

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 9966's short term assets (CN¥1.6B) exceed its short term liabilities (CN¥345.4M).

Uzun Vadeli Yükümlülükler: 9966's short term assets (CN¥1.6B) exceed its long term liabilities (CN¥167.9M).


Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 9966 has more cash than its total debt.

Borcun Azaltılması: 9966 had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Bilanço


Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 9966 has sufficient cash runway for more than 3 years based on its current free cash flow.

Tahmini Nakit Akışı: Insufficient data to determine if 9966 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Sağlıklı şirketleri keşfedin